Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

MLTXMLTX
Showing 8 of 17 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in MoonLake Immunotherapeutics Class A

CITADEL ADVISORS LLC holds 2M shares of MLTX (MoonLake Immunotherapeutics Class A), worth $38.4M as of 2026-Q2. The position was increased (+49.0% shares). MLTX represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$38.4M

Current Shares

2M

Total Value Change

-$78.7M

Total Shares Change

-350,078

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2M
+49.0%
$38.4M0.0%$19.47
40
2026-Q1
Increased
1.3M
+247.5%
$24.7M0.0%$17.69
46
2025-Q4
Increased
380,890
+672.1%
$5M0.0%$13.21
43
2025-Q3
Decreased
49,334
-97.0%
$353,7250.0%$6.24
0
2025-Q2
Increased
1.7M
+13.2%
$79M0.0%$47.52
34
2025-Q1
Decreased
1.5M
-32.4%
$57.8M0.0%$39.86
0
2024-Q4
Decreased
2.2M
-5.9%
$118.4M0.0%$53.02
0
2024-Q3
Increased
2.3M
+2.5%
$117.1M0.0%$49.40
31

Other major holders of MLTX: FMR LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used